From: Primary metastatic prostate cancer between prognosis or adequate/proper medical therapy
Variable | Patient with PSA (< 1 ng/ml) | Patient with PSA (≥ 1 ng/ml) | P |
---|---|---|---|
Patients (n) | 20 | 30 | > 0.05 |
Age (year) (mean ± SD, range) | 70.25 ± 8.17 (52–87) | 70.06 ± 10.91 (52–89) | > 0.05 |
Pre-therapeutic PSA (ng/ml) (median, range) | 26 (8–42) | 82.50 (22–1201) | > 0.05 |
Gleason score (median, range) | 7 (6–9) | 8 (6–9) | > 0.05 |
Cores involved (mean ± SD, range) | 5.19 ± 3.78 (1–12) | 5.50 ± 2.75 (1–11) | > 0.05 |
Percentage of cores involved (mean ± SD, range) | 56.88 ± 31.2 (4–100) | 72.58 ± 23.4 (12.5–100) | > 0.05 |
PSA at last follow-up (ng/ml) (median, range) | 0.12 (0.02–0.90) | 4.64 (1.02–85) | > 0.05 |
Nadir PSA (ng/ml) (median, range) | 0.08 (range 02–0.9) | 2.75 (range 1.05–50) | > 0.05 |
Time to nadir PSA (months) (mean ± SD, range) | 3.50 ± 1.42 (2–7) | 4.03 ± 1.69 (1–7) | > 0.05 |
Bone metastasis (n, %) | 17 (85%) | 24 (80%) | > 0.05 |
Organ metastasis (n, %) | 1 (0.05) | 2 (6.66%) | 0.04 |
Lymph node metastasis (n, %) | 2 (10%) | 4 (13.33%) | 0.04 |
Follow-up (month) (mean ± SD, range) | 13.81 + 9.07 (5–28) | 13.17 + 6.57 (2–30) | > 0.05 |